Drug intelligence / Profile preview

DTT-106

Development stage: Phase 3
Lead developer: EMS
Modality: Small Molecules

Overview

DTT-106 is an investigational small molecule drug developed by EMS Sigma Pharma (EMS SA) for the treatment of erectile dysfunction associated with benign prostatic hyperplasia (BPH). It is currently in Phase 3 clinical trials in Brazil. The precise mechanism of action has not been disclosed and remains unknown. The drug represents a novel approach to managing urogenital diseases, specifically targeting patients experiencing both erectile dysfunction and BPH. No FDA designation or approval has been granted as of June 2025[4][5].

Beyond the preview

Go deeper on DTT-106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DTT-106.

Explore the full profile